The Long-Term Impact of COVID-19 on Oncology Care: A Five-Year Retrospective
Key findings:
- The experimental PGV001 vaccine in combination with an immunotherapy drug was safe and well-tolerated, with only mild injection-site reactions.
- All tested patients developed new, vaccine-specific T cell responses not seen before treatment.
- The personalized vaccine approach proved feasible both for patients with metastatic disease and those receiving treatment after surgery.
Stephanie Blank, MD, discusses the lasting impact of the pandemic on oncology care, including delayed cancer diagnoses and stage migration. Learn more.
